Abstract

BackgroundTumor heterogeneity in breast cancer tumors is today widely recognized. Most of the available knowledge in genetic variation however, relates to the primary tumor while metastatic lesions are much less studied. Many studies have revealed marked alterations of standard prognostic and predictive factors during tumor progression. Characterization of paired primary- and metastatic tissues should therefore be fundamental in order to understand mechanisms of tumor progression, clonal relationship to tumor evolution as well as the therapeutic aspects of systemic disease.MethodsWe performed full exome sequencing of primary breast cancers and their metastases in a cohort of ten patients and further confirmed our findings in an additional cohort of 20 patients with paired primary and metastatic tumors. Furthermore, we used gene expression from the metastatic lesions and a primary breast cancer data set to study the gene expression of the AKAP gene family.ResultsWe report that somatic mutations in A-kinase anchoring proteins are enriched in metastatic lesions. The frequency of mutation in the AKAP gene family was 10% in the primary tumors and 40% in metastatic lesions. Several copy number variations, including deletions in regions containing AKAP genes were detected and showed consistent patterns in both investigated cohorts. In a second cohort containing 20 patients with paired primary and metastatic lesions, AKAP mutations showed an increasing variant allele frequency after multiple relapses. Furthermore, gene expression profiles from the metastatic lesions (n = 120) revealed differential expression patterns of AKAPs relative to the tumor PAM50 intrinsic subtype, which were most apparent in the basal-like subtype. This pattern was confirmed in primary tumors from TCGA (n = 522) and in a third independent cohort (n = 182).ConclusionSeveral studies from primary cancers have reported individual AKAP genes to be associated with cancer risk and metastatic relapses as well as direct involvement in cellular invasion and migration processes. Our findings reveal an enrichment of mutations in AKAP genes in metastatic breast cancers and suggest the involvement of AKAPs in the metastatic process. In addition, we report an AKAP gene expression pattern that consistently follows the tumor intrinsic subtype, further suggesting AKAP family members as relevant players in breast cancer biology.

Highlights

  • Tumor heterogeneity in breast cancer tumors is today widely recognized

  • The number of somatic mutations was significantly different between primary tumor and metastatic lesion The mutational load was significantly greater in metastases, both in recurrently mutated genes, (Fig. 1a) and in all exomic regions (Fig. 1b)

  • Several studies have reported individual A-kinase anchoring proteins (AKAP) genes to be associated with cancer risk and metastatic relapses but no study has so far demonstrated the presence of somatic genetic alterations in clinical metastatic samples

Read more

Summary

Introduction

Tumor heterogeneity in breast cancer tumors is today widely recognized. Most of the available knowledge in genetic variation relates to the primary tumor while metastatic lesions are much less studied. Most studies to date have focused on the primary breast tumor whilst mutational profiles of metastatic lesions and their relationship to the primary tumor have largely been lacking. This has important clinical implications as altered receptor status in the metastatic lesion has been shown to occur at high rates ranging from 14.5–40% for ER 40% for PgR and 0–37% for HER2-receptors during cancer progression [4,5,6] and is affected by adjuvant therapy with major implications for management of the metastatic disease. TCGA data confirms the presence of AKAP somatic point mutations in primary breast cancer with a prevalence of 7% and with a higher rate including copy number variations

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call